Nanobodies® Specific for Respiratory Syncytial Virus Fusion Protein Protect Against Infection by Inhibition of Fusion

Inflammatory signatures for eosinophilic vs. neutrophilic allergic pulmonary inflammation reveal critical regulatory checkpoints

(2011) Pieter Bogaert et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

Nanobodies With In Vitro Neutralizing Activity Protect Mice Against H5N1 Influenza Virus Infection

(2011) Lorena Itatí Ibañez et al.   JOURNAL OF INFECTIOUS DISEASES

Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes

(2011) J. S. McLellan et al.   JOURNAL OF VIROLOGY

Llama-Derived Single Domain Antibodies to Build Multivalent, Superpotent and Broadened Neutralizing Anti-Viral Molecules

(2011) Anna Hultberg et al.   PLoS One

Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers

(2011) K. A. Swanson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Neutralization of Human Respiratory Syncytial Virus Infectivity by Antibodies and Low-Molecular-Weight Compounds Targeted against the Fusion Glycoprotein

(2010) M. Magro et al.   JOURNAL OF VIROLOGY

Respiratory Syncytial Virus-Neutralizing Monoclonal Antibodies Motavizumab and Palivizumab Inhibit Fusion

(2010) K. Huang et al.   JOURNAL OF VIROLOGY

Structural basis of respiratory syncytial virus neutralization by motavizumab

(2010) Jason S McLellan et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Modified Recommendations for Use of Palivizumab for Prevention of Respiratory Syncytial Virus Infections

(2009)   PEDIATRICS

Single-domain antibodies as building blocks for novel therapeutics

(2008) D SAERENS et al.   CURRENT OPINION IN PHARMACOLOGY